CSIMarket


Alterola Biotech Inc   (ALTA)
Other Ticker:  
 


 

Alterola Biotech Inc

ALTA's Financial Statements and Analysis



Alterola Biotech Inc reported break-even for the third quarter of 2024 compare to earnings per share of $0.00 recorded in the same quarter a year ago an improvement compare to $0.00 realized in previous quarter.


third quarter of 2024
Earnings Per Share Revenues
$ 0 $  0 Mill
Unch.     Unch.    



Alterola Biotech Inc 's Revenue fell by 0 % in third quarter of 2024 (Dec 31 2023) year on year, to $0 million and declined by sequentially.


Alterola Biotech Inc is

More on ALTA's Income Statement



Alterola Biotech Inc 's in thethird quarter of 2024 recorded net loss of $-2.010 million, an increase from net loss of $-0.535 million in III. Quarter a year ago.

Sequentially net loss advanced

More on ALTA's Growth

Alterola Biotech Inc Inventories
Inventories grew by 4.96 % to $0 million from III. Quarter a year ago, sequentially inventories rose by 4.1 %. ALTA's Cash flow In the third quarter of 2024 company's net cash flow was $0 million


Alterola Biotech Inc





Company issued 465.11 million shares or 58.13 % in Dec 31 2023.


More on ALTA's Dividends

 Market Capitalization (Millions) 55,872
 Shares Outstanding (Millions) 1,265
 Total Debt (Millions $) 0
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 1




Alterola Biotech Inc





Company issued 465.11 million shares or 58.13 % in Dec 31 2023.


More on ALTA's Balance Sheets

 Market Capitalization (Millions) 55,872
 Shares Outstanding (Millions) 1,265
 Total Debt (Millions $) 0
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 1
   


  News about Alterola Biotech Inc Earnings

Operating Losses Surge for Alterola Biotech Inc in Q4 2023 Financial Report

Alterola Biotech Inc, a legal cannabis company, has r...

Legal Cannabis Company Smashes Expectations with Operating Deficit Shrinking to $-0.47 Million in Q3 2023


Date: January 15, 2024
In the wake of major players in the legal cannabis sector revealing their substantial earnings, attention now turns to smaller businesses within the industry. Among them, ALTA, a company operating principally in the progress stage, has recently reported an operating deficit of $-0.123155 million for the second quarter of 2024. While these losses may seem concerning, a closer look suggests an optimistic trajectory for the company's future performance.
Comparing ALTA's current performance to the same period in 2023, it becomes evident that the recent management strategies have significantly curbed losses. In the July to September 2023 financial span, the company managed to r...

As One of Many Businesses, the ALTA Disclosed a Worrisome Operating Deficit and Revenue Uncertainty in its First Quarter 2024 Results



Alterola Biotech Inc, a prominent player in the legal cannabis sector, recently released its financial results for the first quarter of 2024. With no specified revenue and an operating deficit of $-0.58067 million, the company's current reporting season raises concerns among investors. This article aims to provide context about Alterola Biotech Inc's market position, stock performance, and the implications of its financial figures.
Operating Deficit and Revenue Uncertainty:
One of the major concerns highlighted in Alterola Biotech Inc's Q1 2024 report is the operating deficit of $-0.58067 million. Without any specified revenue, investors are eagerly awaiting additional business strategies a...

Alterola Biotech Inc Defies Expectations: Transforms $-1.75M Operating Deficit into Soaring Growth in Legal Cannabis Market

As a journalist...


Date modified: 2024-02-21T20:25:30+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com